With the objective of transitioning from basic research to antibody diagnosis and treatment, Creative Biolabs has completed several projects in the field of antibody research and development. Equipped with world-leading technology platforms and professional scientific staff, now we provide a variety of anti-tuberculosis antibody products for our clients all over the world.
Introduction of Tuberculosis
Tuberculosis (TB) refers to the infectious disease caused by Mycobacterium tuberculosis (MTB) bacteria. World Health Organization (WHO) states that there will be 10 million cases of tuberculosis (TB) worldwide by 2020 and will kill more than 1 million people annually. Antibiotics are still the mainstay of treatment, and antibody-based diagnostic and therapeutic options are being developed.
Fig.1 Potential mechanisms of action of antibodies in tuberculosis. (Melkie, 2022)
Antibodies in TB Diagnosis
Antibody-based TB diagnosis presents great potential due to cost-effectiveness, ease of implementation, and rapid test performance. A variety of antibodies have been developed for the diagnosis of active tuberculosis (TB) and latent TB infection (LTBI). Of these, the antibody against a mixture of seven MTB antigens exhibited 90% sensitivity and 100% specificity for the diagnosis of PTB. In addition, the use of different types of antibody combinations (IgA, IgM, and IgG) can also further improve the accuracy of serological testing. For example, the combination of anti-16kDa IgA and anti-MPT64 IgA presents more than 90% sensitivity and specificity. What’s more, ELISA-based antibody detection against natural lipid antigens in cell walls showed a novel TB diagnosis method. In summary, monoclonal antibodies play an important role in TB diagnosis.
Antibodies in TB Prophylaxis and Therapy
Since intracellular pathogens that can be targeted by antibodies can be found in the extracellular space, TB protection can theoretically be achieved by the passive transfer of anti-TB antibodies. Intravenous administration of human immunoglobulin (IVIg) to mice has been shown to protect against tuberculosis in animal experiments. Till now, a series of monoclonal antibodies and polyclonal antibodies present prophylactic and therapeutic advantages. For example, vaccination with anti-LAM IgG1 monoclonal antibody effectively reduced bacterial load, suppressed weight loss, and increased survival. Inoculation with anti-Acr monoclonal IgA transiently reduces lung bacterial burden by 10-fold in mice. In addition, the development of TB vaccines, which are designed to target cell-mediated rather than humoral immunity, is also underway.
Learn More about Microbiome Hotspots
Creative Biolabs is a leading service provider that focuses on antibody discovery and production, we are confident in offering the best and most suitable products for our customers. If you are interested in our products, please do not hesitate to contact us for more details.
- Melkie, S.T.; et al. The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group. European Respiratory Review. 2022, 31(163).